onasemnogene abeparvovec

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Spinal Muscular AtrophiesSpinal Muscular Atrophy (SMA)

Phase 3

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

Active, not recruitingNCT05335876

Novartis PharmaceuticalsSpinal Muscular Atrophy (SMA)

Start: 2022-12-19End: 2031-04-30Updated: 2026-07-09

Unknown Phase

A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

RecruitingNCT06019637

Novartis PharmaceuticalsSpinal Muscular Atrophies

Start: 2023-11-22End: 2038-09-30Target: 50Updated: 2025-01-15

Related Papers

Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study.

2024-12-309 citations